GRÜNENTHAL PRESENTS PHASE III RESULTS FOR QUTENZA® IN POST-SURGICAL NEUROPATHIC PAIN AT IASP 2026 WORLD CONGRESS ON PAIN

Contributed by: News Aktuell

Issued by news aktuell/OTS on behalf of Grünenthal Group

Logo

Tags

Medical profession

Research

More Like This

GRÜNENTHAL LICENSES EXCLUSIVE AUSTRALIAN RIGHTS TO QUTENZA® TO CLINECT

GRÜNENTHAL LICENSES EXCLUSIVE SOUTH KOREAN RIGHTS TO QUTENZA® TO BCWORLD PHARM

APOTEX LICENSES EXCLUSIVE CANADIAN RIGHTS TO QUTENZA® FROM GRÜNENTHAL

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 2026

GRÜNENTHAL PARTNERS WITH DKSH TO BRING FOUR IMPORTANT PAIN MEDICINES TO EIGHT NEW MARKETS IN ASIA-PACIFIC

GRÜNENTHAL ADVANCES PROPRIETARY NOCICEPTIN RECEPTOR (NOP) AGONIST INTO PHASE II TRIAL IN ACUTE PAIN

GRÜNENTHAL SUCCESSFULLY COMPLETES PHASE I TRIAL WITH NOCICEPTIN RECEPTOR (NOP) AGONIST

EQT Life Sciences leads USD 56 million Series D financing in Neuros Medical to commercialize FDA-approved treatment for post-amputation pain